BeOne Medicines AG DRC (ONC)

Currency in USD
319.94
+9.94(+3.21%)
Closed·
326.26+6.32(+1.98%)
·

NASDAQ:ONC Financials

Key Ratios

P/E Ratio123.74
Price/Book7.77
Debt / Equity25.06%
Return on Equity7.46%
Dividend Yield0.00%
EBITDA578.82M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
* In Millions of USD (except for per share items)

Analyst Ratings

24 Buy
2 Hold
0 Sell
Ratings:
26 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 408.20
(+27.59% Upside)

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
1.95 / 1.53
Revenue / Forecast
1.5B / 1.46B
EPS Revisions
Last 90 days

FAQ

What were BeOne Medicines DRC's earnings for the latest quarter?

The BeOne Medicines DRC EPS (TTM) is 2.47. BeOne Medicines DRC reported sales of The BeOne Medicines DRC EPS (TTM) is 2.47. BeOne Medicines DRC reported sales of 1,498.17, net income of 66.50, and EPS of 1.95 for the latest quarter., net income of 66.50, and EPS of 1.95 for the latest quarter.

What was BeOne Medicines DRC's net income for the latest quarter?

BeOne Medicines DRC's net income for the latest quarter was 66.50.

How did BeOne Medicines DRC's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1,412.28 million USD in the previous quarter to 1,498.17 million USD in the latest quarter, and net income moved from 124.84 million USD to 66.50 million USD compared to the previous quarter.

What is BeOne Medicines DRC's net profit margin on a TTM basis?

BeOne Medicines DRC's trailing twelve months (TTM) net profit margin is 5.37%%.

How does BeOne Medicines DRC's debt to equity ratio compare to industry standards?

BeOne Medicines DRC's total debt-to-equity ratio is 25.06%.

What is BeOne Medicines DRC's return on investment on a TTM basis?

BeOne Medicines DRC's trailing twelve months (TTM) return on investment (ROI) is 7.46%.

What is BeOne Medicines DRC's gross margin on a TTM basis?

BeOne Medicines DRC's trailing twelve months (TTM) gross margin is 87.49%%.

What was BeOne Medicines DRC's revenue per share for the latest quarter?

BeOne Medicines DRC's revenue per share for the latest quarter was 3.61.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.